High Triglycerides and Gout Risk
Elevated triglycerides are independently associated with increased gout risk, particularly in men, and should be recognized as both a metabolic comorbidity requiring treatment and a potential contributor to gout development.
The Association Between Triglycerides and Gout
Direct Evidence of Association
The relationship between high triglycerides and gout is well-established through multiple lines of evidence:
EULAR guidelines explicitly identify hyperlipidemia as an associated comorbidity that should be addressed as an important part of gout management 1. The metabolic syndrome—which includes elevated triglycerides—is recognized as a cluster of conditions strongly associated with raised serum uric acid and gout 1, 2.
Prospective research demonstrates that hypertriglyceridemia (triglycerides >150 mg/dL) independently increases gout risk even after adjusting for other metabolic factors 3. In men with hyperuricemia, hypertriglyceridemia conferred a hazard ratio of 1.38 for developing gout, and notably, this risk persisted even in men WITHOUT hyperuricemia (HR 1.40) 3.
Mendelian randomization studies confirm causality: each standard deviation increase in triglycerides (~112 mg/dL) was associated with a 0.10 mg/dL increase in serum urate 4. This genetic evidence suggests the relationship is not merely correlational but potentially causal.
Mechanisms Linking Triglycerides to Gout
The connection operates through several pathways:
VLDL particles (which carry triglycerides) contain apolipoprotein B, which has been shown to regulate neutrophil response to monosodium urate crystals 5. Increased VLDL triglycerides are specifically associated with gout risk compared to asymptomatic hyperuricemia, with each mmol/L increase in VLDL triglycerides conferring an odds ratio of 7.61 for gout in Europeans 5.
Insulin resistance serves as a critical mediator. The triglyceride-glucose (TyG) index—a marker of insulin resistance—shows strong associations with gout, with each unit increase associated with 40% higher odds of gout 6. Over 57% of excess hyperuricemia risk can be attributed to the interaction between genetic factors and elevated TyG index 7.
Clinical Implications for Management
Assessment Priorities
When evaluating patients with gout or hyperuricemia:
Measure fasting triglycerides as part of metabolic syndrome screening 1, 2. Cutoffs: 150-199 mg/dL (mild), 200-999 mg/dL (moderate), ≥1,000 mg/dL (severe) 8.
Recognize that 27% of adults have mild-to-moderately elevated triglycerides, largely driven by obesity and diabetes 9.
Assess for secondary causes: uncontrolled diabetes, excessive alcohol intake, medications (thiazides, beta blockers, corticosteroids), hypothyroidism, renal disease 8, 10.
Treatment Strategy
Lifestyle interventions are first-line for both conditions 1, 10:
- Weight loss in obese patients (reduces serum uric acid from 570 to 470 μmol/L over 16 weeks) 1
- Low purine diet
- Alcohol reduction (especially beer and spirits, which independently increase gout risk) 1
- Avoidance of refined carbohydrates 10
Pharmacologic considerations:
- Statins are reasonable for moderate-to-severe hypertriglyceridemia in patients with ASCVD risk ≥7.5% 10, and have modest triglyceride-lowering effects (10-15%) 8
- Fenofibrate reduces both serum uric acid AND triglycerides 1, making it particularly useful when both conditions coexist
- For severe hypertriglyceridemia (≥500 mg/dL), fibrates may be necessary to prevent pancreatitis 10
Common Pitfalls to Avoid
Don't dismiss elevated triglycerides as merely a marker—the evidence suggests a causal pathway to gout development, particularly through insulin resistance and VLDL metabolism 5, 4.
Don't overlook triglycerides in normouricemic patients with gout—hypertriglyceridemia increases gout risk even without hyperuricemia 3.
Don't treat gout in isolation—the metabolic syndrome components (including hypertriglyceridemia) require integrated management for optimal outcomes 1, 2.
In women, general obesity (BMI >27) shows stronger independent association with gout than in men (HR 2.19 in women without hyperuricemia vs. 1.40 for hypertriglyceridemia in men) 3, suggesting sex-specific metabolic pathways.
The evidence consistently demonstrates that elevated triglycerides contribute to gout risk through multiple mechanisms, warrant screening in all gout patients, and should be addressed through both lifestyle modification and appropriate pharmacotherapy as part of comprehensive gout management.